Sandbox Rim: Difference between revisions
Rim Halaby (talk | contribs) No edit summary |
Rim Halaby (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
==FIRE: Focused Initial Rapid Evaluation== | |||
A Focused Initial Rapid Evaluation (FIRE) should be performed to identify patients in need of immediate intervention. | |||
| | <span style="font-size:85%">Boxes in the red color signify that an urgent management is needed.</span> | ||
{{Family tree/start}} | |||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | A00 | | A00=<div style="float: left; text-align: left; width: 35em; padding:1em;"> '''Identify cardinal findings of unstable angina/ NSTEMI :''' <br> | |||
|style=" | ❑ '''[[Chest pain|<span style="color:white;"> Chest pain</span>]] or [[chest discomfort|<span style="color:white;">chest discomfort</span>]]''' <br> | ||
| | :❑ Sudden onset | ||
| | :❑ Sensation of heaviness, tightness, pressure, or squeezing | ||
:❑ Duration> 20 minutes (but usually less than half an hour) <br> | |||
|style=" | :❑ Radiation to the left arm, jaw, neck, right arm, back or [[epigastrium|<span style="color:white;">epigastrium</span>]] | ||
| style=" | :❑ No relief with medications<br> | ||
:❑ No relief with rest <br> | |||
| style=" | :❑ Worse with time <br> | ||
:❑ Worse with exertion<br> | |||
| style=" | :❑ Associated symptoms of [[palpitations|<span style="color:white;">palpitations</span>]], [[nausea|<span style="color:white;">nausea</span>]], [[vomiting|<span style="color:white;">vomiting</span>]], [[sweating|<span style="color:white;">sweating</span>]], [[dyspnea|<span style="color:white;">dyspnea</span>]], and | ||
[[lightheadedness|<span style="color:white;">lightheadedness</span>]] | |||
| style=" | ❑ '''Characteristic [[ECG|<span style="color:white;">ECG</span>]] changes consistent with [[unstable angina|<span style="color:white;">unstable angina</span>]]/ [[NSTEMI|<span style="color:white;">NSTEMI</span>]] ''' | ||
| | :❑ No changes <br> | ||
|style=" | :❑ Non specific ST / T wave changes <br> | ||
|} | :❑ Flipped or inverted T waves <br> | ||
:❑ ST depression (carries the poorest prognosis) <br> | |||
❑ '''Increase in >99th percentile of upper limit of normal of [[troponin|<span style="color:white;">troponin</span>]] and / or [[CKMB|<span style="color:white;">CK MB </span>]]''', which is consistent with [[NSTEMI|<span style="color:white;">NSTEMI</span>]]</div>}} | |||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | |!| | | }} | |||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | G02 | G02= <div style="float: left; text-align: left; width: 35em; padding:1em;"> '''Rule out life threatening alternative diagnoses:'''<br> | |||
❑ [[Aortic dissection|<span style="color:white;">Aortic dissection</span>]] <br> (suggestive findings: [[back pain|<span style="color:white;">back pain</span>]], [[interscapular pain|<span style="color:white;">interscapular pain</span>]], [[aortic regurgitation|<span style="color:white;">aortic regurgitation</span>]], [[pulsus paradoxus|<span style="color:white;">pulsus paradoxus</span>]], [[blood pressure|<span style="color:white;">blood pressure</span>]] discrepancy between the arms) <br> | |||
❑ [[Pulmonary embolism|<span style="color:white;">Pulmonary embolism</span>]] <br> (suggestive findings: acute onset of [[dyspnea|<span style="color:white;">dyspnea</span>]], [[tachypnea|<span style="color:white;">tachypnea</span>]], [[hemoptysis|<span style="color:white;">hemoptysis</span>]], previous [[DVT|<span style="color:white;">DVT</span>]]) <br> | |||
❑ [[Cardiac tamponade|<span style="color:white;">Cardiac tamponade</span>]] <br> (suggestive findings: [[hypotension|<span style="color:white;">hypotension</span>]], [[jugular venous distention|<span style="color:white;">jugular venous distention</span>]], [[muffled heart sounds|<span style="color:white;">muffled heart sounds</span>]], [[pulsus paradoxus|<span style="color:white;">pulsus paradoxus</span>]])<br> | |||
❑ [[Tension pneumothorax|<span style="color:white;">Tension pneumothorax</span>]] <br> (suggestive findings: sudden [[dyspnea|<span style="color:white;">dyspnea</span>]], [[tachycardia|<span style="color:white;">tachycardia</span>]], [[trauma|<span style="color:white;">chest trauma</span>]], unilateral absence of [[breath sounds|<span style="color:white;">breath sound</span>]])<br> | |||
❑ [[Esophageal rupture|<span style="color:white;">Esophageal rupture</span>]] <br> (suggestive findings: [[vomiting|<span style="color:white;">vomiting</span>]], [[subcutaneous emphysema|<span style="color:white;">subcutaneous emphysema</span>]])</div>}} | |||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | |!| | | }} | |||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | A01 | | | | | A01= <div style="float: left; text-align: left; width: 25em; padding:1em;">'''Begin initial treatment:'''<br> ❑ Administer [[aspirin|<span style="color:white;">aspirin</span>]] | |||
:❑ 162 to 325 mg of non enteric [[aspirin|<span style="color:white;">aspirin</span>]],orally, crushed or chewed, THEN | |||
:❑ 75 to 325 mg/day | |||
❑ Administer 2-4 L/min [[oxygen|<span style="color:white;">oxygen</span>]] via nasal cannula when saturation <90% | |||
:❑ Caution in [[COPD|<span style="color:white;">COPD</span>]] patients: maintain an oxygen saturation between 88% and 92% | |||
❑ Administer [[beta-blockers|<span style="color:white;">beta-blockers</span>]] (unless contraindicated) and titrate to the [[heart rate|<span style="color:white;">heart rate</span>]] and [[blood pressure|<span style="color:white;">blood pressure </span>]]<br> | |||
<span style="font-size:85%;">Contraindicated in [[heart failure|<span style="color:white;">heart failure </span>]], [[AV block |<span style="color:white;">prolonged or high degree AV block </span>]], [[reactive airway disease|<span style="color:white;">reactive airway disease </span>]], high risk of [[cardiogenic shock|<span style="color:white;">cardiogenic shock </span>]] and low [[cardiac output|<span style="color:white;">cardiac output</span>]] state</span> <br> | |||
:❑ [[Metoprolol|<span style="color:white;">Metoprolol</span>]] IV, 5 mg every 5 min, up to 3 doses, then 25 to 50 mg orally every 6 hours | |||
:❑ [[Carvedilol|<span style="color:white;">Carvedilol</span>]] IV, 25 mg, two times a day | |||
❑ Administer sublingual [[nitroglycerin|<span style="color:white;">nitroglycerin</span>]] 0.4 mg every 5 minutes for a total of 3 doses<br> | |||
<span style="font-size:85%;">Contraindicated in suspected [[RVMI|<span style="color:white;">right ventricular MI </span>]], recent use of [[phosphodiesterase inhibitors|<span style="color:white;">phosphodiesterase inhibitors </span>]], decreased [[blood pressure|<span style="color:white;">blood pressure </span>]] 30 mmHg below baseline</span> <br> | |||
❑ Administer IV [[morphine|<span style="color:white;">morphine</span>]] if persistent symptoms or [[pulmonary edema|<span style="color:white;">pulmonary edema</span>]] | |||
:❑ Initial dose 4-8 mg | |||
:❑ 2-8 mg every 5 to 15 minutes, as needed <br> | |||
❑ Administer 80 mg [[atorvastatin|<span style="color:white;">atorvastatin</span>]] <br> | |||
❑ Monitor with a 12-lead [[ECG|<span style="color:white;">ECG</span>]] all the time | |||
</div>}} | |||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | |!| | | }} | |||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | G01 | G01= <div style="float: left; text-align: left; width: 35em; padding:1em;"> '''Does the patient have any of the following indications that require immediate angiography and revascularization ?''' | |||
❑ Hemodynamic instability or [[cardiogenic shock|<span style="color:white;">cardiogenic shock </span>]] <br> | |||
❑ Severe left ventricular dysfunction or [[heart failure|<span style="color:white;">heart failure </span>]] <br> | |||
❑ Recurrent or persistent rest angina despite intensive medical therapy <br> | |||
❑ New or worsening [[mitral regurgitation|<span style="color:white;">mitral regurgitation </span>]] or new [[VSD|<span style="color:white;">VSD </span>]] <br> | |||
❑ Sustained [[VT|<span style="color:white;">VT </span>]] or [[VF|<span style="color:white;">VF </span>]]<br> | |||
❑ Prior [[PCI|<span style="color:white;">PCI </span>]] within past 6 months or [[CABG|<span style="color:white;">CABG </span>]] <br> </div> }} | |||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |,|-|-|^|-|-|.| | }} | |||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | C01 | | | | C02 | | | C01=<div style="float: left; text-align: center; width: 25em; padding:1em;">'''YES''' </div>| C02= <div style="float: left; text-align: center; width: 25em; padding:1em;">'''NO''' </div> }} | |||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| | | | | C03 | | | C03=<div style="float: left; text-align: center; width: 25em; padding:1em;">'''Calculate the risk of patients:'''<br> | |||
❑ [[TIMI risk score|<span style="color:white;">Thrombolysis in Myocardial Infarction (TIMI) risk score</span>]], OR | |||
❑ [[GRACE score|<span style="color:white;">GRACE score</span>]] </div>}} | |||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| | | |,|-|^|-|.| | }} | |||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | D01 | | D02 | | D03 | |D01=<div style="float: left; text-align: center; width: 20em; padding:1em;"> '''Proceed to [[angiography|<span style="color:white;">angiography </span>]]'''<br></div> | |||
| D02= <div style="float: left; text-align: center; width: 20em; padding:1em;"> '''Low risk''' <br> '''Initial conservative strategy''' </div> | |||
| D03= <div style="float: left; text-align: center; width: 20em; padding:1em;"> '''High risk''' <br> '''Initial invasive strategy''' </div>}} | |||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| | | |!| | | |!| | }} | |||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | A01 | | D01 | | D02 |A01=<div style="float: left; text-align: left; width: 25em; padding:1em;"> | |||
'''Administer ONE of the following antiplatelet agents (before or at the time of PCI):''' <br> | |||
❑ [[P2Y12|<span style="color:white;">P2Y12</span>]] receptor inhibitors <br> | |||
:❑ [[Clopidogrel|<span style="color:white;">Clopidogrel</span>]] 600 mg | |||
:❑ [[Ticagrelor|<span style="color:white;">Ticagrelor</span>]] 180 mg | |||
:❑ [[Prasugrel|<span style="color:white;">Prasugrel</span>]] 60 mg <br> | |||
<span style="font-size:85%;">Prasugrel is contraindicated in case of prior history of strokes or TIAs, active pathological bleeding, age ≥75 years, when urgent coronary artery bypass graft surgery (CABG) is likely, body weight <60 kg, propensity to bleed, concomitant use of medications that increase the risk of bleeding </span> <br> | |||
❑ IV [[GP IIb/IIIa inhibitors|<span style="color:white;">GP IIb/IIIa inhibitors</span>]] <br> | |||
:❑ [[Abciximab|<span style="color:white;">Abciximab</span>]]<br> | |||
::❑ Loading dose 0.25 mg/kg IV bolus <br> | |||
::❑ Maintenance dose 0.125 mg/kg/min <br> | |||
:❑ [[Eptifibatide|<span style="color:white;">Eptifibatide</span>]]<br> | |||
::❑ Loading dose 180 mcg/kg IV bolus | |||
::❑ Another 180 mcg/kg IV bolus after 10 minutes<br> | |||
::❑ Maintenance dose 2 mcg/kg/min <br> | |||
::❑ Decrease infusion by 50% if creatinine clearance <50 mL/min | |||
::❑ Avoid in hemodialysis patients | |||
:❑ [[Tirofiban|<span style="color:white;">Tirofiban</span>]] <br> | |||
::❑ Loading dose 25 mcg/kg<br> | |||
::❑ Maintenance dose 0.15 mcg/kg/min | |||
::❑ Decrease infusion by 50% if [[creatinine|<span style="color:white;">creatinine</span>]] clearance <30 mL/min | |||
---- | |||
'''Administer ONE of the following anticoagulant therapy:'''<br> | |||
❑ [[UFH|<span style="color:white;">Unfractionated heparin</span>]] <br> | |||
:♦ ''If GP IIb/IIIa receptor antagonist is planned'' | |||
:❑ 50- to 70-U/kg IV bolus <br> | |||
:♦ ''If no GP IIb/IIIa receptor antagonist is planned'' | |||
:❑ 70- to 100-U/kg bolus <br> | |||
❑ [[Bivalirudin|<span style="color:white;">Bivalirudin</span>]] | |||
::❑ 0.75-mg/kg IV bolus, then 1.75–mg/kg/h infusion | |||
::❑ Additional bolus of 0.3 mg/kg if needed | |||
::❑ Decrease infusion to 1 mg/kg/h when [[creatinine|<span style="color:white;">creatinine</span>]] clearance <30 mL/min | |||
</div>|D01=<div style="float: left; text-align: left; width: 20em; padding:1em;"> '''Administer one of the following antiplatelet agents:'''<br> | |||
❑ [[Clopidogrel|<span style="color:white;">Clopidogrel </span>]]<br> | |||
:❑ Loading dose (300 mg)<br> | |||
:❑ Maintenance dose for up to 12 months (75 mg)<br> | |||
❑ [[Ticagrelor|<span style="color:white;">Ticagrelor </span>]] | |||
:❑ Loading dose (180 mg)<br> | |||
:❑ Maintenance dose for up to 12 months (90 mg twice daily)</div>|D02=<div style="float: left; text-align: left; width: 20em; padding:1em;"> '''Administer one of the following antiplatelet agents:'''<br> | |||
'''Before [[PCI|<span style="color:white;">PCI </span>]]'''<br> | |||
❑ [[P2Y12|<span style="color:white;">P2Y12 </span>]] receptor inhibitors <br> | |||
:❑ [[Clopidogrel|<span style="color:white;">Clopidogrel </span>]] (600 mg), or<br> | |||
:❑ [[Ticagrelor|<span style="color:white;">Ticagrelor </span>]](180 mg), or <br> | |||
❑ IV [[GP IIb/IIIa|<span style="color:white;">GP IIb/IIIa </span>]] inhibitors <br> | |||
:❑ [[Eptifibatide|<span style="color:white;">Eptifibatide </span>]]<br> | |||
::❑ Loading dose 180 mcg/kg IV bolus followed by another bolus after 10 minutes<br> | |||
::❑ Maintenance dose 2 mcg/kg/min, or <br> | |||
:❑ [[Tirofiban|<span style="color:white;">Tirofiban </span>]]<br> | |||
::❑ Loading dose 25 mcg/kg<br> | |||
::❑ Maintenance dose 0.15 mcg/kg/min<br> | |||
'''At the time of [[PCI|<span style="color:white;">PCI </span>]]'''<br> | |||
❑ [[P2Y12|<span style="color:white;">P2Y12 </span>]] receptor inhibitors <br> | |||
:❑ [[Clopidogrel|<span style="color:white;">Clopidogrel </span>]] (600 mg), or<br> | |||
:❑ [[Ticagrelor|<span style="color:white;">Ticagrelor </span>]] (180 mg), or <br> | |||
:❑ Prasugrel (60 mg)<br> | |||
❑ IV [[GP IIb/IIIa|<span style="color:white;">GP IIb/IIIa </span>]] inhibitors <br> | |||
:❑ [[Eptifibatide|<span style="color:white;">Eptifibatide </span>]]<br> | |||
::❑ Loading dose 180 mcg/kg IV bolus followed by another bolus after 10 minutes<br> | |||
::❑ Maintenance dose 2 mcg/kg/min, or <br> | |||
:❑ [[Tirofiban|<span style="color:white;">Tirofiban</span>]] <br> | |||
::❑ Loading dose 25 mcg/kg<br> | |||
::❑ Maintenance dose 0.15 mcg/kg/min </div>}} | |||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| | | |!| | | |!| | }} | |||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | A01 | | A02 | | A03 | |A01=<div style="float: left; text-align: left; width: 25em; padding:1em;"> '''Consider urgent [[CABG|<span style="color:white;">CABG</span>]] if the coronary anatomy is not amenable to PCI and one of the following:'''<ref name="www.ncbi.nlm.nih.gov">{{Cite web | last = | first = | title = ACC/AHA 2004 guideline update for coronary arter... [Circulation. 2004] - PubMed - NCBI | url = http://www.ncbi.nlm.nih.gov/pubmed?term=15466654 | publisher = | date = | accessdate = }}</ref> <br> ❑ Patients with left main or left main equivalent disease <br> ❑ Patients with three or two vessel disease involving the left anterior descending artery with left ventricular dysfunction <br> ❑ Diabetic patients </div>|A02=<div style="padding: 5px; background: #FFFFFF; text-align: center;">'''[[Unstable angina/ NSTEMI resident survival guide#Complete Diagnostic Approach|Continue with the complete diagnostic approach below]]''' </div>|A03=<div style="float: left; text-align: left; width: 25em; padding:1em;"> ❑ Perform an [[angiography|<span style="color:white;">angiography</span>]] </div>}} | |||
{{familytree/end}} |
Revision as of 20:42, 6 April 2015
FIRE: Focused Initial Rapid Evaluation
A Focused Initial Rapid Evaluation (FIRE) should be performed to identify patients in need of immediate intervention.
Boxes in the red color signify that an urgent management is needed.
Identify cardinal findings of unstable angina/ NSTEMI : ❑ Chest pain or chest discomfort
lightheadedness ❑ Characteristic ECG changes consistent with unstable angina/ NSTEMI
| |||||||||||||||||||||||
Rule out life threatening alternative diagnoses: ❑ Aortic dissection (suggestive findings: vomiting, subcutaneous emphysema) | |||||||||||||||||||||||
Begin initial treatment: ❑ Administer aspirin
❑ Administer 2-4 L/min oxygen via nasal cannula when saturation <90%
❑ Administer beta-blockers (unless contraindicated) and titrate to the heart rate and blood pressure
❑ Administer sublingual nitroglycerin 0.4 mg every 5 minutes for a total of 3 doses
❑ Administer 80 mg atorvastatin | |||||||||||||||||||||||
Does the patient have any of the following indications that require immediate angiography and revascularization ?
❑ Hemodynamic instability or cardiogenic shock | |||||||||||||||||||||||
YES | NO | ||||||||||||||||||||||
Calculate the risk of patients: ❑ Thrombolysis in Myocardial Infarction (TIMI) risk score, OR ❑ GRACE score | |||||||||||||||||||||||
Proceed to angiography | Low risk Initial conservative strategy | High risk Initial invasive strategy | |||||||||||||||||||||
Administer ONE of the following antiplatelet agents (before or at the time of PCI):
Prasugrel is contraindicated in case of prior history of strokes or TIAs, active pathological bleeding, age ≥75 years, when urgent coronary artery bypass graft surgery (CABG) is likely, body weight <60 kg, propensity to bleed, concomitant use of medications that increase the risk of bleeding
Administer ONE of the following anticoagulant therapy:
| Administer one of the following antiplatelet agents:
| Administer one of the following antiplatelet agents: Before PCI
❑ IV GP IIb/IIIa inhibitors
At the time of PCI
❑ IV GP IIb/IIIa inhibitors
| |||||||||||||||||||||
❑ Perform an angiography | |||||||||||||||||||||||